Prosecution Insights
Last updated: April 17, 2026
Application No. 17/819,159

TOPICAL SKIN TREATMENT COMPOSITION

Non-Final OA §103
Filed
Aug 11, 2022
Examiner
JUSTICE, GINA CHIEUN YU
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
unknown
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
3y 4m
To Grant
63%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allow Rate
520 granted / 944 resolved
-4.9% vs TC avg
Moderate +8% lift
Without
With
+8.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
48 currently pending
Career history
992
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
15.5%
-24.5% vs TC avg
§112
20.4%
-19.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 944 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-4 are rejected under 35 U.S.C. 103 as being unpatentable over Eckart et al. (EP 0884046 A1, published December 16, 1998) (“Eckart” hereunder) in view of Dahm (WO 2002015862 A1, published on February 28, 2002), Kim et al. (KR 1020130088226, published on August 8, 2013) (“Kim” hereunder), Tomlinson et al. (US 2018/0318202 A1, published November 8, 2018) (“Tomlinson” hereunder). Eckart teaches a cosmetic composition for improved photoprotective properties, the composition comprising water (76.225 wt %), vitamin C phosphate 0.1 wt %, panthenol 1 wt %, glycerin 3 wt %, xanthan gum 0.1 wt %, tocopherol acetate 1 wt % and sodium hydroxide (45 %) 0.45wt %. The reference further teaches adding preservatives such as 4-hydroxybenzoic acid and salts, etc. See p. 4, col. 2, lines 29 – 40. Although Eckart suggests any vitamin C or derivatives can be used, the reference fails to teach L-ascorbic acid. Dahm teaches a photoprotective composition comprising 0.1-10wt % of L-ascorbic with light protective agents in cosmetic emulsions. The reference teaches that L-ascorbic acid potentiate the light protection effect and reduces the lipid peroxide exposure of the skin. It is prima facie obvious to combine or substitute art-recognized equivalents in order to form a third composition useful for the same purpose. See MPEP 2144. 06. In this case, since Eckart and Dahm establish that vitamin C phosphate and L-ascorbic acid are used in photoprotective composition, combining the two vitamin C derivatives or substituting one for the other to make another photoprotective composition with vitamin C properties would have been prima facie obvious. Eckart fails to teach flaxseed extract. Kim teaches a cosmetic composition comprising flaxseed extract, which is effective in reducing skin pore and improving acne. The reference teaches that 0.01-97 wt % of flaxseed extract can be used based on the weight of the composition. See translation, abstract. Examples show formulations comprising 10 wt % of flaxseed extract. See translation, Examples 1-3. Suitable formulations include cream, lotion, ointment, etc. See translation. It would have been obvious to one of ordinary skill in the art before the time of the effective filing date of the present application to modify the teachings of Eckart and incorporate to the composition flaxseed extract as motivated by Kim, as the latter teaches its efficacy in reducing skin pore and improving acne. Since both references are directed to cosmetic compositions in similar forms, the skilled artisan would have had a reasonable expectation of successfully producing a stable and improved external composition that can reduce skin pores and treats acne. Eckhard fails to teach gluconolactone. Although Eckhard teaches using preservatives such as sorbic acid salts, 4-hydroxybenzoic acid and benzyl alcohol among others, the reference fails to specifically disclose potassium sorbitan and sodium benzoate. See p. 4, col. 2, lines 31. Tomlinson teaches that gluconolactone is an acidic compound that is gentle on the skin and provides anti-wrinkle effects on the skin, optimally functioning at a lower pH condition. The reference teaches that a combination of gluconolactone and a form of vitamin C improves skin care condition, which include improving skin exfoliation, moisturization, wrinkles and fine lines, skin sagging or hyperpigmentation from UV exposure, increase skin firmness or skin laxity. See [0018]. The reference teaches that 0.001 to 10 wt % of an O-substituted ascorbic acid or its derivatives and 0.01-20 wt % of gluconolactone or derivatives can be used in a composition comprising up to 90 wt % of an aqueous phase. See [0029]. Tomlinson teaches that suitable preservatives for the skin care composition include potassium sorbate, benzoic acid, sodium benzoate, benzyl alcohol, etc, used in an amount from 0.01 to 10 wt %. See [0096]. It would have been obvious to one of ordinary skill in the art before the time of the effective filing date of the present application to modify the teachings of Eckart and incorporate to the composition gluconolactone as motivated by Tomlinson, as the latter teaches combined use with vitamin C in improving skin exfoliation, moisturization, wrinkles and fine lines, skin sagging or hyperpigmentation from UV exposure, increasing skin firmness or skin laxity. Since both references are directed to cosmetic compositions comprising vitamin C, the skilled artisan would have had a reasonable expectation of successfully producing a stable and improved external composition that provides improved skin conditioning effects including antiaging properties, exfoliation, moisturization, etc. Since Eckart teaches using sorbic acid salts as a preservative, using specific salt such as potassium sorbate as motivated by Tomlinson would have been prima facie obvious. Since Eckart and Tomlinson disclose cosmetically suitable preservatives including benzyl alcohol, benzoic acid salts such as sodium benzoate, etc, combining these or substituting one for the other would have been prima facie obvious. Tomlinson further teaches aloe vera and panthenol are skin conditioning agents and used in an amount ranging from 0.1-10 wt % or 0.5 – 7 wt %. See [0091]. Including such skin conditioning agents for the expected cosmetic benefits would have been prima facie obvious. Regarding claim 2, generally, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” See In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). In this case, the cited references disclose the suggested concentration ranges of the cosmetic actives and the expected functions and outcome. For example, Dahm teaches that L-ascorbic acid is useful as a light protecting agent and can be used up to 10 wt %; Kim teaches flaxseed extract is used at 10wt % in formulations. Finding suitable concentrations of the ingredients to optimize the efficacy and stability by routine experimentation would have only taken ordinary skill in the art. Regarding claim 3, although Eckart does not specifically disclose the method step of adding the components, selection of any order of mixing ingredients is prima facie obvious. See MPEP 2144.04, IV C. Furthermore, claim 3 is a product-by-process claim. “[E]ven though product-by-process claims are limited by and defined by the a product does not depend on its method of production. If the product in the product-by- process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (citations omitted). In this case, prior art teaches, suggests and motivates one of ordinary skill in the art to combine and make the composition as presently claimed as indicated above, and the composition of claim 3 would still be obvious regardless of the method of adding the ingredients, unless shown otherwise. Regarding claim 4, Tomlinson teaches adjusting the composition with sodium hydroxide to 4.5 and 6.5. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GINA JUSTICE whose telephone number is (571)272-8605. The examiner can normally be reached M-F 8:30 AM - 5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JOHANN RICHTER can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GINA C JUSTICE/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Aug 11, 2022
Application Filed
Dec 16, 2023
Non-Final Rejection — §103
Jul 11, 2024
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599610
SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST
2y 5m to grant Granted Apr 14, 2026
Patent 12599548
Method of Treating Oxidative Stress in Skin and Compositions Therefor
2y 5m to grant Granted Apr 14, 2026
Patent 12589105
HUMAN MILK FORTIFIER COMPOSITION
2y 5m to grant Granted Mar 31, 2026
Patent 12582605
EXTENDED RELEASE FORMULATIONS OF CANNABINOIDS
2y 5m to grant Granted Mar 24, 2026
Patent 12582636
PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING PROTON PUMP INHIBITOR AND ANTACID
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
63%
With Interview (+8.2%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 944 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month